- Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy MADISON, Wis., Dec.

REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as the only "preferred" ...

Exact Sciences Corporation EXAS recently presented new data highlighting the clinical value of the Oncotype DX Breast Recurrence Score test at the 2021 San Antonio Breast Cancer Symposium (SABCS). The ...

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early ...

Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score(R) ...

In what's believed to be one of the largest population-based studies of Oncotype DX ever conducted, researchers at The University of Texas MD Anderson Cancer Center have found that the commercial ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

Title: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. Presenter: Ivana Sestak, Ph.D. Date: Friday, Dec.9, 2016: 4:15 p.m. CT. Location: S6-05; General Session 6 - ...

(NIH) has developed the Genetic Testing Registry (GTR), a free online resource, to provide physicians, researchers and patients with detailed and accurate information about genetic and genomic tests.

At first glance, given that the two assays share only one overlapping gene, it would appear that the two assays have little in common in terms of genomic content. However, the priority gene lists are ...